Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Public ClinicalTrials.gov record NCT05980416. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Express CLDN18.2
Study identification
- NCT ID
- NCT05980416
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Elevation Oncology
- Industry
- Enrollment
- 88 participants
Conditions and interventions
Conditions
Interventions
- EO-3021 Drug
- Ramucirumab (CYRAMZA®) Drug
- Dostarlimab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2023
- Primary completion
- May 6, 2025
- Completion
- Jun 1, 2025
- Last update posted
- Nov 13, 2025
2023 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| City of Hope | Duarte | California | 91010 | — |
| Yale - Smilow Cancer Hospital | New Haven | Connecticut | 06519 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Johns Hopkins University - Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | Florida | 32827 | — |
| Henry Ford Cancer | Detroit | Michigan | 48202 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Atrium Health/Wake Forest University | Charlotte | North Carolina | 28204 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| UW Carbone Cancer Center - Cancer Connect | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05980416, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 13, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05980416 live on ClinicalTrials.gov.